Collectively, these findings highlight a distinct therapeutic sensitivity profile of MYCN-overexpressing retinoblastoma cells, particularly to transcriptional inhibitors (THZ1, Flavopiridol) and the PLK1 inhibitor Volasertib. The gene discussed is PLK1; the disease is retinoblastoma.